Close Menu

NEW YORK – Twist Bioscience announced on Wednesday after the close of the market the pricing of an upsized $300 million public offering of common stock at $110 per share.

The South San Francisco, California-based firm will offer approximately 2.8 million shares, including 75,000 shares to be sold by certain shareholders.

Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares at the public offering price, less the underwriting discount and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.